# Mechanisms of AS01B Adjuvant in CD4 T Cell Activation ## AS01B adjuvant mechanisms and CD4 T cell responses AS01B induces robust and durable CD4 T cell responses via a two-phase mechanism of transient inflammatory cytokine induction followed by sustained IFN-signaling pathway activation that drives context-dependent Th1 or Th2 polarization. ## Abstract AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination. The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation. ## Methods We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. **Records from Elicit search** - n = 200 - Papers screened using: AS01B Adjuvant Focus, CD4 T Cell Response Measurement, Appropriate Study Type, AS01B Data Availability, CD4 T Cell Data Inclusion, CD4 T Cell Response Focus, AS01B Effect Attribution, Full Publication Status - n = 200 Papers screened out - n = 190 Papers included for extraction ## Paper search We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/). We ran this query: “AS01B adjuvant mechanisms and CD4 T cell responses” and retrieved 200 papers most relevant. ## Screening We screened in sources based on abstracts that met key criteria: - **AS01B Adjuvant Focus**: Investigates AS01B adjuvant specifically. - **CD4 T Cell Response Measurement**: Measures CD4 T cell responses as primary or secondary outcomes. - **Appropriate Study Type**: Human clinical trial or established animal study. - **AS01B Data Availability**: Includes AS01B data. - **CD4 T Cell Data Inclusion**: Includes CD4 T cell data. - **CD4 T Cell Response Focus**: Focuses on CD4 T cell response data. - **AS01B Effect Attribution**: Specific attribution of AS01B adjuvant effects. - **Full Publication Status**: Full-text publication. All screening questions were considered to make judgments on screening in each paper. ## Data extraction We asked a large language model to extract each data column below from each paper. - **Study Context**: Key study design information relevant to AS01B adjuvant mechanisms. - **AS01B Mechanisms**: Mechanistic data showing how AS01B works at the innate immunity level. - **CD4 Responses**: CD4 T cell response data specifically for AS01B. - **Mechanism-Response Links**: Evidence connecting AS01B mechanisms to CD4 T cell responses. - **Adjuvant Comparisons**: Comparative data between AS01B and other adjuvants. - **Key Findings**: Main conclusions and key findings about AS01B adjuvant mechanisms. ## Results ### Characteristics of included studies | Study | Full text retrieved? | Study population | Antigen used with AS01B | Study design | Adjuvants compared | Sample size (AS01B group) | |-------------------------------------------|----------------------|-------------------------------|--------------------------------------------------|-------------------------------------|-----------------------------------------|-------------------------| | K. Kester et al., 2009 | No | Healthy human adults | RTS,S antigen | Double-blind, randomized trial | AS01B, AS02A | ~51 participants | | M. Fochesato et al., 2016 | Yes | C57BL6 mice | VZV glycoprotein E (gE) | Comparative immunogenicity study | AS01B, AS01E, AS03, AS04 | Not mentioned | | G. Leroux-Roels et al., 2016 | No | Healthy HBV-naïve adults | HBsAg | Phase II, randomized, multicenter trial | AS01B, AS01E, AS03A, AS04, Alum | Not mentioned | | I. Leroux-Roels et al., 2010 | No | Healthy HIV-seronegative adults | gp120/NefTat candidate HIV-1 vaccine | Randomized double-blind | AS01B, AS02A, AS02V | Not mentioned | | P. Vandepapelière et al., 2008 | No | Healthy adults | Recombinant hepatitis B surface antigen | Randomised, double-blind | AS01B, AS02B, AS02V, CpG oligonucleotide | Not mentioned | | C. Nielsen et al., 2021 | Yes | Human | Plasmodium falciparum merozoite protein (PfRH5) | Comparative platform study | AS01B vs. heterologous viral vectors | 57 out of 64 vaccinees | | W. Burny et al., 2017 | Yes | Healthy HBV-naïve adults aged 18-45 years | Hepatitis B virus (HBV) surface antigen (HBsAg) | Randomized, controlled phase II trial | AS01B, AS01E, AS03, AS04, Alum | ~58 participants | | S. Pichyangkul et al., 2004 | No | Rhesus monkeys | Recombinant Plasmodium falciparum MSP1(42) antigen | Comparative immunogenicity study | AS01B, AS02A, AS05, AS08, Alum | Not mentioned | | G. Leroux-Roels et al., 2014 | No | Healthy adults aged 21 to 41 years | Recombinant fusion protein (F4) | Randomized | AS01B (with/without chloroquine) | Not mentioned | | C. Brando et al., 2006 | No | Three inbred strains of mice (BALB/c, A/J, C57BL/6J) | FMP011 (recombinant LSA1 protein) | Comparative immunogenicity study | AS01B, AS02A | Not mentioned | ### AS01B mechanisms at the innate immunity level | Study | Cytokines induced | Signaling pathways | Timeline of responses | Gene expression changes | |-------------------------------------------|-------------------------------------------|---------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------| | K. Kester et al., 2009 | Interleukin-2, INFγ, TNFα, CD40L | Not mentioned | Not mentioned | Not mentioned | | M. Fochesato et al., 2016 | IFN-γ | Not explicitly mentioned | Antigen-specific CD4+ T cells detected at 30 days after dosing | Not mentioned | | P. Vandepapelière et al., 2008 | High IFN-γ, moderate IL-5, IL-2 | Not mentioned | Strongest and most durable responses after two doses | Not mentioned | | C. Nielsen et al., 2021 | IL-4, IL-5, IL-13 | PPAR, FcεRI, TGF-β | Not mentioned | Increased expression of genes related to PPAR, FcεRI, and TGF-β pathways | | W. Burny et al., 2017 | IL-6, IFN-γ, CRP, IP-10 | IFN-signaling pathway | Peak IL-6 at 24 hours, IFN-γ and IP-10 increases at days 31 and 33 | Upregulation of IFN-inducible genes STAT1, IRF1, MX1, and CXCL10 at day 31 | | S. Pichyangkul et al., 2004 | IFN-γ | Not mentioned | IFN-γ response persisted at least 24 weeks after final vaccination | Not mentioned | AS01B consistently induced IFN-γ production across multiple studies. Burny et al. demonstrated that AS01B induced transient innate responses including IL-6 and CRP, which peaked at 24 hours post-vaccination. After the second injection, AS01B increased IFN-γ levels and upregulated IFN-inducible genes suggesting AS01B may activate both Th1-associated and Th2-associated pathways based on context. ### CD4 T cell responses induced by AS01B | Study | CD4 T cell markers/frequencies | Cytokine production | Functional assays | Persistence/durability | CD4 subset analysis | |-------------------------------------------|---------------------------------------------------|--------------------------------------|--------------------------------------|------------------------------------|-------------------------------------| | K. Kester et al., 2009 | Median 963 vs 308 CSP-specific CD4+ T cells per 10^6 CD4+ T cells (AS01B vs AS02A) | Higher ex vivo IFN-γ ELISPOTs | Ex vivo IFN-γ ELISPOTs: mean 212 vs 96 spots/million cells | Implied by rechallenge data | Not mentioned | | M. Fochesato et al., 2016 | GMF 6.2% (Exp 1) and 9.1% (Exp 2) for AS01B | IFN-γ and IL-2 | Intracellular staining | Not mentioned | Focus on IFN-γ positive cells (Th1 response) | | G. Leroux-Roels et al., 2016 | Significantly higher frequencies in AS01B and AS01E groups | Not mentioned | Not mentioned | Not mentioned | Similar polyfunctionality profiles across adjuvants | | I. Leroux-Roels et al., 2010 | High lymphoproliferative capacity | IL-2 production | Not mentioned | Still detectable 18 months after last immunization | Not mentioned | | P. Vandepapelière et al., 2008 | Vigorous lymphoproliferation | High IFN-γ, moderate IL-5, IL-2 | Not mentioned | Strongest after two doses | Not mentioned | | C. Nielsen et al., 2021 | Higher-frequency antigen-specific CD4+ T cell response | Lower Th1:Th2 cytokine ratios | AIM assay showed robust PfRH5-specific response | Significant differences noted at day 14 and day 63 | Higher proportion of Th2 and Tfh2 cells | | W. Burny et al., 2017 | Not mentioned | Increased IFN-γ levels after second injection | Not mentioned | Not mentioned | Not mentioned | | S. Pichyangkul et al., 2004 | High stimulation indices for lymphocyte proliferation (27-50) | Strong Th1 response indicated by IFN-γ/IL-5 ratio | Not mentioned | IFN-γ response persisted at least 24 weeks | Strong Th1 response | | G. Leroux-Roels et al., 2014 | Characterized by intracellular cytokine staining and lymphoproliferation | Not specifically mentioned | Intracellular cytokine staining and lymphoproliferation assays| Persisted for at least 3 years after primary vaccination and 6 months after booster | Not mentioned | | C. Brando et al., 2006 | Not mentioned | IFN-γ production | Intracellular staining, ELISpot analysis | Not mentioned | CD4+ cells main IFN-γ producers | AS01B consistently induced robust CD4 T cell responses across diverse antigens and species, demonstrating exceptional durability of CD4 responses. It also revealed context-dependent Th1/Th2 skewing with stronger responses generally favoring Th1. ### Comparative adjuvant effects | Adjuvant | CD4 T cell response magnitude (relative to AS01B) | Mechanistic profile | Key distinguishing features | |-----------|-----------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------| | AS01B | Baseline | IFN-signaling pathway activation, IL-6, IFN-γ, CRP, IP-10 | Strongest CD4 responses, highest IFN-γ production, activation of IFN-signaling pathway | | AS01E | Similar to AS01B | Comparable innate profiles to AS01B | Contains 50% less MPL and QS-21 than AS01B, induced lower CD4 responses than AS01B | | AS02A | Lower than AS01B | Balanced Th1/Th2 response | 32% efficacy vs 50% for AS01B, median 308 vs 963 CSP-specific CD4+ T cells | | AS03 | Lower than AS01B | IFN-signaling pathway activation | AS01B showed 5.4-fold greater CD4 response than AS03 | | AS04 | Lower than AS01B | Similar to Alum | AS01B showed 2.8-fold greater CD4 response than AS04 | | Alum | Lowest of all adjuvants | Basic innate responses without IFN-signaling | Consistently lowest in adaptive response rankings | ### Mechanistic links between AS01B activation and CD4 T cell responses The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses. Transient inflammatory mediators (IL-6, CRP) peak shortly after vaccination, followed by delayed activation of the IFN-signaling pathway after the second dose. This dual-phase process drives robust CD4 T cell responses characterized by high magnitude, extended durability, and context-dependent polarization. AS01B’s unique formulation plays a critical role in enhancing vaccine immunogenicity through complementary mechanisms for T cell activation.